Related Experiment Video
Updated: Jun 6, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Bladder cancer: Restaging TUR reduces recurrence and progression risk
1Sidney Kimmel Center for Prostate and Urologic Cancers, 353 East 68th Street, New York, NY 10021, USA. dalbagng@mskcc.org
Nature Reviews. Urology
|December 9, 2010
Summary
A second transurethral resection (TUR) for early bladder cancer lowers progression risk. This restaging TUR is now recommended for stage T1 bladder cancer patients.
Area of Science:
- Oncology
- Urology
Background:
- Transurethral resection (TUR) is a primary treatment for early-stage bladder cancer.
- The efficacy of a second, or restaging, TUR in improving patient outcomes requires further investigation.
Discussion:
- A restaging TUR significantly reduces the risk of bladder cancer progression.
- This procedure is also linked to a decreased likelihood of cancer-related mortality.
Key Insights:
- Restaging TUR is a crucial intervention for patients diagnosed with stage T1 bladder cancer.
- Implementing restaging TUR as a standard of care can enhance survival rates and reduce disease advancement.
Outlook:
- Further research should focus on long-term outcomes and quality of life following restaging TUR.
- Exploring variations in restaging TUR protocols may optimize patient management strategies.
